TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Photon/Proton Radiation Therapy for Oropharyngeal Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven squamous cell carcinoma of oropharynx (tonsillar pillars, tonsillar fossa, soft palate, base of tongue).~* Stage-grouping:~  * Stage I (T1N0)~ * Stage II (T2N0)~ * Favorable Stage III (T1N1/T2N1) and selected stage IV (T1-T2 early N2b)2 or less lymph node and 2 or less cm diameter lymph node~ * Unfavorable stage III and selected stage IV (any T, N2c/N3)~* Surgery of the primary tumor/lymph nodes is limited to incisional/excisional biopsies.~* Will receive treatment with proton radiation.~Exclusion Criteria:~* Evidence of distant metastasis.~* Previous irradiation for head and neck cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Photon/Proton Radiation Therapy (Type: None): Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mothers of preterm infants~* Pumping breast milk~Exclusion Criteria:~* Neonatal congenital anomalies

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \>= 18 years~* written informed consent~Group A - patients with thermal burns~* partial thickness burns (2nd degree) requiring non-surgical primary treatment~* primarily 5-15% TBSA burns, but burn patients with injury size from 1 to 40% TBSA may be included~or~Group B - patients with thermal burns~* non-grafted partial thickness burns (2nd degree) in patients requiring autotransplantation in the early phase~* primarily 5-15% TBSA burns, but burn patients with injury size from 1 to 40% TBSA may be included~or~Group C - patients with thermal burns~* donor site(s) on the ventral side of the body and limbs in deep partial thickness burns (2nd degree) and/or full thickness burns patients requiring autotransplantation during the first 1-3 weeks after injury~* primarily 5-15% TBSA burns, but burn patients with injury size from 1 to 40% TBSA may be included~Exclusion Criteria:~* inhalation injury to airways and lungs~* chemical or high voltage electrical burn~* pregnancy, lactation~* clinical signs or symptoms of acute infection~* any prescription or non-prescription topical medication administered within one week prior to study start~* hematological and clinical/chemical parameteres judged as unacceptable by the investigator~* donor sites with re-harvesting~* previous treatment with soluble beta-1,3/1,6-glucan~* participation in other clinical studies in the last 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes Mellitus~* Dyslipidemia~* Undergoing elective PCI~Exclusion Criteria:~* Patients with recent Acute Coronary Syndrome (≤1 month)~* Patients on dual antiplatelet treatment (DAPT) with ticagrelor or prasugrel~* Patients undergoing urgent/emergent PCI for stent thrombosis~* Severe acute or chronic medical or psychiatric condition~* Pregnancy~* Participation in another experimental clinical trial, without formal approval~* Unwillingness or inability to comply with the requirements of this protocol

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- evolocumab 420mg (Type: ACTIVE_COMPARATOR): 75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
- placebo (Type: PLACEBO_COMPARATOR): 75 subjects on optimal statin therapy undergoing elective PCI will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be between 18 years and 65 years of age~* WHO Class II-III~* Diagnosis of one of the following Group I WHO clinical classifications: Idiopathic or familial pulmonary arterial hypertension (PAH) or PAH associated with a collagen vascular disease or PAH associated with congenital systemic-to-pulmonary shunt repaired greater than 5 years prior to study entry or PAH associated with portal hypertension with mild or moderate hepatic dysfunction or PAH associated with drugs or toxins.~* Receiving inhaled iloprost for at least two months prior to screening or prior to treatment discontinuation.~* May have discontinued iloprost treatment against medical advice up to thirty days prior to screening~* Be mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.~Exclusion Criteria:~* Be a nursing or pregnant woman~* Have any PAH medication, other than inhaled iloprost, discontinued within the week prior to study entry.~* Received any prostacyclin or prostacyclin analog except iloprost in the past 3 months.~* Previous history of significant parenchymal lung disease~* Have any other type of PAH including but not limited to PAH related to thrombotic or embolic disease~* Have evidence of left-sided heart disease~* Musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable.~* Uncontrolled systemic hypertension or chronic renal insufficiency~* Use of an investigational drug within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 65 and older~* Elective cardiac or thoracic aortic surgery~* Capable and willing to consent~* Participants literate in English~Exclusion Criteria:~* Emergency Surgery~* Major Neurological Disease~* Gross Cognitive Dysfunction~* Patients not expected to be able to complete the 1 week and 3 months post-operative visit.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes (Type: ACTIVE_COMPARATOR): Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
- Patients with SctO2 less than 60 %. (Type: NO_INTERVENTION): The study patients will not get any intervention in this arm if the Sct02 falls below 60%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥ 18 years old~2. Informed consent~3. Beneficiaries of a social security plan~4. Vaccinated or unvaccinated against SARS-COV-2:~   * Vaccinated individuals have had a 3rd dose for at least one month, or have been infected with SARS-Cov-2 and have had 2 doses of vaccine for at least one month~  * Unvaccinated persons are naïve to previous SARS Cov 2 infection~5. Positive nasopharyngeal RT-PCR test for selection with a Ct viral load ≤ 23~6. Have a phone and internet connection to access the entry application~Exclusion Criteria:~1. The participant is related to any member of the study staff or has a close relationship or conflict of interest with the sponsor.~2. Known hypersensitivity or allergy to any component of the test product.~3. Contraindication to nasal spray~4. Insufficient vaccination: any incomplete vaccination schedule~   * either a 3rd dose within the last month~  * or SARS-Cov-2 infection with less than 2 vaccine doses or with 2 vaccine doses less than 1 month old.~5. Any condition, including COVID, that is likely to result in hospitalization during study participation.~6. Conditions that may result in hospitalization during study participation.~7. Known pregnancy or positive urine pregnancy test at D0 by the nurse, or current breastfeeding~8. Participation in an antiviral clinical trial or other trial using a medical device for disease prevention COVID 19

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced Water S-100 ionized nasal spray (Type: EXPERIMENTAL): 2 sprays in each nostril, 6 times a day during 8 days
- Nasal spray with purified water (Type: PLACEBO_COMPARATOR): 2 sprays in each nostril, 6 times a day during 8 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a patient who has complex perianal fistula~* a patient who is negative in pregnancy test~* a patient who has submitted a written consent~Exclusion Criteria:~* a patient who has participated in other clinical studies within 30 days before this clinical trial or has not passed 5 fold period of a half-life of other investigational drugs.~* a patient who has a history of variant Creutzfeldt Jacobs disease or related diseases~* a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue~* a patient who has an autoimmune disease~* a patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)~* a patient who has sepsis or active tuberculosis~* a patient who is pregnant or breast feeding~* a patient who has inflammatory Bowel disease~* over 2cm in diameter of fistula

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Low dose group
- Group 2 (Type: EXPERIMENTAL): high dose group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of cholangiocarcinoma that has been established preoperatively by at least one of the following criteria:~   1. A positive brush cytology or biopsy result obtained at the time of cholangiography;~  2. Fluorescence in situ hybridization demonstrating aneuploidy;~  3. A serum CA 19-9 value greater than 100 U/mL in the presence of a radiographically characteristic malignant stricture in the absence of cholangitis.~  4. Listed for OLT for hilar cholangiocarcinoma~2. Tumor/stricture is above the cystic duct and is unresectable.~3. A suitable candidate for orthotopic liver transplantation as judged by the liver transplant team. All 3 treatment modalities are not needed to confirm eligibility for this registry trial.~4. \>/= 18 years of age.~5. Willing and able to provide written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients with unresectable cholangiocarcinoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects, in otherwise good health, 20 to 55 years of age~* Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache~* Subjects with a minimum of 1 migraine attack per month~* Attack duration of 4 to 72 hours~* Normal attack intensity of at least 4 on a 0-10 VAS-scale~Exclusion Criteria:~* Completed heart surgery~* Cardiovascular diseases~* Vascular damages on neck vessels~* Diseases other than migraine of the CNS~* Severe disease of vital body organs~* Severe psychiatric disorders~* More than 6 migraine attacks per month

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Migraine medical device (Type: EXPERIMENTAL): Treatment with an active nasal probe
- Inactive migraine medical device (Type: PLACEBO_COMPARATOR): Treatment with an inactive nasal probe.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CarboMedics Top Hat vs St. Jude Medical Regent Valve Comparing Sizing and Hemodynamics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are indicated for implant with a mechanical valve prosthesis in the aortic position according to the current practice for valve selection at the center.~Exclusion Criteria:~* Patients \< 18 years of age~* Emergency surgery~* Pre-existing valve prosthesis~* Aortic root replacement~* Active endocarditis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): CarboMedics Supra-annular Top Hat Valve
- 2 (Type: ACTIVE_COMPARATOR): St. Jude Medical Regent Valve

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.~* Lansky Index \> 60%.~* Left ventricular ejection fraction \> 39%.~* Negative HIV serology.~* Provide informed consent in accordance with current legislation.~Exclusion Criteria:~* Patients with a history of poor compliance.~* Patients not valid after psycho-social evaluation~* Severe (4) functional organ disorders (hepatic, renal, respiratory) according to NCI CTCAE v3 criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Activated natural killer cells (Type: EXPERIMENTAL): Activated natural killer cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* ≥ 8 years of age and \< 19 years of age at the time of registration~* Newly diagnosed with cancer~* Chemotherapy naive~* Scheduled to receive moderately or highly emetogenic chemotherapy (non-steroid containing regimen) as an in-patient. (Refer to Appendix IV. In multiple agent regimens, select the agent with the highest emetic potential.)~* Scheduled for placement of IV accesses device(s) for treatment purposes (allowing a dedicated line for continuous infusion of study agent)~* Not pregnant or lactating~EXCLUSION CRITERIA:~* Prior chemotherapy~* Central Nervous System disease~* Stem cell transplant while on-study~* Out-patient chemotherapy~* Steroids are included in their chemotherapy regimen~* Contraindication to the use of dexamethasone (e.g. diabetes)~* Hepatic and/or renal failure~* Allergic to any of the study medications~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Benadryl® Ativan® Decadron® (BAD) Pump (Type: EXPERIMENTAL): Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
- Control Arm Saline (Type: ACTIVE_COMPARATOR): Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 45 years or older or \< 45 years old with family history of CRC~* Speak and read English or Spanish~* Current resident in Clallam county~* Currently non-adherent to CRC screening recommendations~Exclusion Criteria:~* Age \< 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Screening (S2S education, FIT kit) (Type: EXPERIMENTAL): Participants receive S2S online screening education and FIT kit for sample collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Training in Evidence-based Practices for Clinicians Who Work With Migrant Workers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BA level social work student~* Bilingual Spanish Speaking~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Traditional Training (Type: ACTIVE_COMPARATOR): 20 hours of didactic education and training in CBT principles, depression assessment and cultural competency and 25 hours in dyad role playing of CBT manualized treatment sessions with supervision.
- ITS based training (Type: EXPERIMENTAL): Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues